Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study

masaki shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, Masatoshi Eto

Research output: Contribution to journalArticle

Abstract

This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3% of patients, including 25.4% who achieved a ≥ 50% decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0%, 33.3%, and 23.8% of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.

Original languageEnglish
Article number32
JournalMedical Oncology
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Safety
Drug Therapy
Survival
Treatment Failure
Disease-Free Survival
Febrile Neutropenia
Neutropenia
cabazitaxel
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy : a multi-institutional study. / shiota, masaki; Nakamura, Motonobu; Yokomizo, Akira; Tomoda, Toshihisa; Sakamoto, Naotaka; Seki, Narihito; Hasegawa, Shuji; Yunoki, Takakazu; Harano, Masahiko; Kuroiwa, Kentaro; Eto, Masatoshi.

In: Medical Oncology, Vol. 36, No. 4, 32, 01.04.2019.

Research output: Contribution to journalArticle

shiota, masaki ; Nakamura, Motonobu ; Yokomizo, Akira ; Tomoda, Toshihisa ; Sakamoto, Naotaka ; Seki, Narihito ; Hasegawa, Shuji ; Yunoki, Takakazu ; Harano, Masahiko ; Kuroiwa, Kentaro ; Eto, Masatoshi. / Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy : a multi-institutional study. In: Medical Oncology. 2019 ; Vol. 36, No. 4.
@article{4b9713fcf74e46dc9b14defd8951e0bd,
title = "Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study",
abstract = "This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3{\%} of patients, including 25.4{\%} who achieved a ≥ 50{\%} decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0{\%}, 33.3{\%}, and 23.8{\%} of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.",
author = "masaki shiota and Motonobu Nakamura and Akira Yokomizo and Toshihisa Tomoda and Naotaka Sakamoto and Narihito Seki and Shuji Hasegawa and Takakazu Yunoki and Masahiko Harano and Kentaro Kuroiwa and Masatoshi Eto",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s12032-019-1257-1",
language = "English",
volume = "36",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy

T2 - a multi-institutional study

AU - shiota, masaki

AU - Nakamura, Motonobu

AU - Yokomizo, Akira

AU - Tomoda, Toshihisa

AU - Sakamoto, Naotaka

AU - Seki, Narihito

AU - Hasegawa, Shuji

AU - Yunoki, Takakazu

AU - Harano, Masahiko

AU - Kuroiwa, Kentaro

AU - Eto, Masatoshi

PY - 2019/4/1

Y1 - 2019/4/1

N2 - This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3% of patients, including 25.4% who achieved a ≥ 50% decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0%, 33.3%, and 23.8% of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.

AB - This multi-institutional study aimed to investigate the efficacy and safety profiles of cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate cancer (CRPC). This study included 63 Japanese patients with CRPC who were treated with cabazitaxel from 2014 to 2017. The oncological outcomes and adverse events (AEs) were documented, and prognostic factors for oncological outcomes and predictive factors for AEs were analysed. PSA decline was observed in 68.3% of patients, including 25.4% who achieved a ≥ 50% decline. The median progression-free survival, treatment failure-free survival, and overall survival were 4.3, 4.1, and 9.0 months, respectively. More cycles of prior docetaxel therapy was identified as common favourable prognostic factors for progression-free survival, treatment failure-free survival, and overall survival. Severe neutropenia, febrile neutropenia, and severe non-haematological AEs were observed in 73.0%, 33.3%, and 23.8% of patients, respectively. However, > 10 cycles of docetaxel was not associated with increased incidence of AEs. In conclusion, cabazitaxel chemotherapy was still active in Japanese CRPC patients treated with > 10 cycles of docetaxel chemotherapy, with an acceptable risk of AE burden. Treatment with cabazitaxel after > 10 cycles of docetaxel may be an appropriate option when it can be administered.

UR - http://www.scopus.com/inward/record.url?scp=85062213854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062213854&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1257-1

DO - 10.1007/s12032-019-1257-1

M3 - Article

C2 - 30815799

AN - SCOPUS:85062213854

VL - 36

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 4

M1 - 32

ER -